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Introduction
• Esophageal Carcinoma
– Estimated 18,400 new cases in 
the US in 2020
– 5 year survival between 19% –
22%
• Tumor Staging for Esophageal 
Carcinoma
– Sentinel Lymph Node 
identification and staging
• Endoscopic Ultrasound Guided 
Biopsy – 38% - 51% accuracy
• Radionuclide, Blue Dye, and CT 
– 85% accuracy
– Prognostic significance
Introduction
• Contrast Enhanced Endoscopic 
Lymphsonography (CEUS)
– Enhanced imaging of lymph nodes
using Ultrasound Contract Agents
– “Contrast‐Enhanced Ultrasound 
Imaging of Sentinel Lymph Nodes 
After Peritumoral Administration of 
Sonazoid in a Melanoma Tumor 
Animal Model”
• Goldberg et al
• 82% accuracy in detecting Sentinel 
Lymph Nodes (SLN)
Objectives
& Hypothesis
• Research Question
– How will Contrast Enhanced Lymphsonography
(CEUS) compare to Endoscopic Ultrasound (EUS) in 
the identification of Sentinel Lymph Nodes and 
overall tumor staging in adult patients with 
esophageal carcinoma? 
• Hypothesis
– The use of CEUS in lymph node biopsy will increase 
the percentage of malignancy positive SLNs biopsied 
as compared to EUS and provide more accurate 
tumor staging.
Approach & Results
• Study design 
– Unblinded Pilot Study
• Population / study sample
– 40 patients at TJUH recently diagnosed with esophageal carcinoma
• Intervention
– Contrast Enhanced Lymphsonography
• Data source and collection 
– Comparison of patient’s contrast enhanced exam with their own 
unenhanced exam 
• All patients will undergo non-contrast EUS and suspicious nodes will 
be identified and biopsied (standard of care)
• Peritumor injection of ultrasound contrast agent, Sonazoid, will be 
administered and suspicious nodes by CEUS will be biopsied
• All biopsied specimens will be assessed for presence of cancer 
spread by qualified pathologist
Approach & Results
• Analysis 
• Calculation of metastasis identification, accuracy of SLN identification, sensitivity, 
specificity, PPV, and NPV of CEUS and EUS sampled lymph nodes
• Pathology as reference standard
• Findings
Conclusions
• EUS-guided FNA biopsy - metastasis positive rate of 40% (10/20) 
• CEUS-guided biopsy - metastasis positive rate of 63% (12/19)
• 4 participants (29%) had nodal status upgrade with the addition of CE-
EUS findings
– altering their clinical management and future course of therapy
CEUS guided FNA
• Accuracy – 61.9%
• Sensitivity – 80%
• Specificity – 16.7%
• PPV – 70.6%
• NPV – 25%
EUS guided FNA
• Accuracy – 33.3%
• Sensitivity – 26.7%
• Specificity – 50%
• PPV – 57.1%
• NPV – 21.4%
CE-EUS identification and FNA of SLN may increase cytologic yield by ruling 
out nodes not associated with the tumor drainage pattern and identifying 
SLNs with metastatic deposits not seen by EUS. These findings highlight the 
current shortcomings of EUS nodal staging in esophageal cancer and the 
important clinical improvements that can be achieved even by modestly 
improving SLN identification.
Future Directions
• Larger trial to improve statistical significance
– Increase length of the study to follow clinical 
outcomes
• Comparison of different contrast agents
• Effectiveness of Ultrasound Contrast Agent in
different cancers
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